Source-grounded facts extracted from GE HealthCare Technologies Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
George A. Newcomb changed role as Controller and Chief Accounting Officer at GE HealthCare Technologies Inc..
“George A. Newcomb, who currently serves as GE HealthCare’s interim Chief Financial Officer, will cease serving in that interim role on September 14, 2026, and will continue serving as GE HealthCare’s Controller and Chief Accounting Officer.”
William K. Grogan was appointed as Chief Financial Officer at GE HealthCare Technologies Inc..
“On August 13, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (“GE HealthCare”) appointed William K. Grogan as Chief Financial Officer, effective September 14, 2026.”
George Newcomb was appointed as interim Chief Financial Officer at GE HealthCare Technologies Inc..
“On July 23, 2026, GE HealthCare named George Newcomb, Controller and Chief Accounting Officer, as interim Chief Financial Officer, effective August 14, 2026.”
James K. (Jay) Saccaro resigned as Chief Financial Officer at GE HealthCare Technologies Inc..
“On July 21, 2026, James K. (Jay) Saccaro notified GE HealthCare that he will resign as Chief Financial Officer for a role outside of the medical technology industry.”
GE HealthCare Technologies Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent auditor for fiscal year 2026 at the 2026-05-07 meeting.
“Our stockholders ratified the appointment of Deloitte & Touche LLP as our independent auditor for the fiscal year ending December 31, 2026, based on the following voting results: Votes For Votes Against Abstentions Broker Non-Votes 398,257,878 769,608 440,327 —”
GE HealthCare Technologies Inc. shareholders approved Advisory vote to approve named executive officers' compensation at the 2026-05-07 meeting.
“Our stockholders approved our named executive officers’ compensation in an advisory vote, based on the following voting results: Votes For Votes Against Abstentions Broker Non-Votes 351,099,781 12,973,200 795,207 34,599,625”
GE HealthCare Technologies Inc. shareholders approved Election of eight directors to serve until 2027 annual meeting at the 2026-05-07 meeting.
“Our stockholders elected eight directors to each serve a one-year term until our 2027 annual meeting of stockholders or until his or her successor has been elected and qualified, based on the following voting results: Nominee Votes For Votes Against Abstentions Broker Non-Votes Peter J. Arduini 363,637,737 735,813 494,638 34,599,625 H. Lawrence Culp, Jr. 351,620,004 12,409,707 838,477 34,599,625 Rodney F. Hochman 360,969,846 3,400,154 498,188 34,599,625 Catherine Lesjak 362,377,938 2,071,223 419,027 34,599,625 Kevin A. Lobo 332,339,981 32,058,693 469,514 34,599,625 Anne T. Madden 361,399,817 2,837,076 631,295 34,599,625 William J. Stromberg 361,023,279 3,319,101 525,808 34,599,625 Phoebe L. Yang 361,640,539 2,588,148 639,501 34,599,625”
GE HealthCare Technologies Inc. updated its first quarter ended March 31, 2026 guidance (reaffirmed).
“On April 29, 2026 , GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its first quarter 2026 financial results.”
GE HealthCare Technologies Inc. incurred revolving credit of $0.5 billion with JPMorgan Chase Bank, N.A., as administrative agent at alternate base rate, a daily simple SOFR rate, or an adjusted Term SOFR rate for maturing February 25, 2027.
“On February 26, 2026, GE HealthCare Technologies Inc. (the “Company”) entered into a 364-Day Revolving Credit Agreement (the “New Revolving Credit Agreement”) among the Company, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders named therein, which provides for a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $0.5 billion.”
GE HealthCare Technologies Inc. terminated 2025 364-Day Revolving Credit Agreement with JPMorgan Chase Bank, N.A. and the lenders named therein valued at $0.5 billion (effective 2026-02-26).
“In connection with the Company’s entry into the New Revolving Credit Agreement, the 2025 364-Day Revolving Credit Agreement, which provided for a $0.5 billion 364-day senior unsecured revolving credit facility, was terminated without penalty on February 26, 2026.”
GE HealthCare Technologies Inc. entered into New Revolving Credit Agreement with JPMorgan Chase Bank, N.A. and the lenders named therein valued at $0.5 billion (effective 2026-02-26).
“On February 26, 2026, GE HealthCare Technologies Inc. (the “Company”) entered into a 364-Day Revolving Credit Agreement (the “New Revolving Credit Agreement”) among the Company, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders named therein, which provides for a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $0.5 billion.”
GE HealthCare Technologies Inc. incurred term loan of $750 million with JPMorgan Chase Bank, N.A., as administrative agent maturing third anniversary.
“On December 12, 2025, GE HealthCare Technologies Inc. (the “Company”) entered into a three-year senior unsecured term loan credit facility (the “Term Loan Credit Agreement”) among the Company, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders named therein. Pursuant to the Term Loan Credit Agreement, the lenders thereunder have committed to make an unsecured term loan in an aggregate amount of $750 million (the “Term Loan”), which will be made in a single borrowing on a future date subject to the satisfaction (or waiver) of certain customary conditions precedent, and will mature and be payable in full on the third anniversary thereof.”
GE HealthCare Technologies Inc. incurred revolving credit of $3.0 billion with JPMorgan Chase Bank, N.A. at alternate base rate or an adjusted Term SOFR rate for a one-, three-, or six-mon maturing March 27, 2030.
“Chase Bank, N.A., as administrative agent, and the lenders named therein, which provides for a senior unsecured revolving credit facility in an aggregate committed amount of $3.0 billion. The 2025 Credit Agreement and the 2025 364-Day Revolving Credit Agreement are each referred to herein as a “New Credit Agreement” and collectively as the “New Credit”
GE HealthCare Technologies Inc. incurred revolving credit of $0.5 billion with JPMorgan Chase Bank, N.A. at alternate base rate or an adjusted Term SOFR rate for a one-, three-, or six-mon maturing March 26, 2026.
“Bank, N.A., as administrative agent, and the lenders named therein, which provides for a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $0.5 billion, and (ii) a Credit Agreement (the “2025 Credit Agreement”) among the Company, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders named therein, which provides”
GE HealthCare Technologies Inc. reported the first quarter ended March 31, 2024 results: revenue $4.6 billion, net income $374 million, EPS $0.81. Guidance reaffirmed.
“of 2024 consistent with our previous comments, and we remain on track to deliver our guidance for the year.” First Quarter 2024 Total Company Financial Performance • Revenues of $4.6 billion declined 1% r eported and were approximately flat on an Organic* basis year-over-year, with decreased volume partially offset by positive price. • Total company book-to-bill was”
Jan Makela resigned as Chief Executive Officer, Imaging at GE HealthCare Technologies Inc..
“On April 9, 2024, Jan Makela, Chief Executive Officer, Imaging, notified GE HealthCare Technologies Inc. (the “Company”) that he will be resigning from his role at the Company to become the chief executive officer of a private company that is not one of the Company’s competitors.”
GE HealthCare Technologies Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
“On February 6, 2024 , GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its fourth quarter and fiscal year ended December 31, 2023 financial results.”
GE HealthCare Technologies Inc. reported the fiscal year ended December 31, 2023 results: revenue $19.6 billion, net income $1.6 billion, EPS $3.04. Guidance reaffirmed.
“million versus $109 million for the prior year. • Segment EBIT margin was 24.4% versus 23.0% for the prior year. Full Year 2023 Total Company Financial Performance • Revenues of $19.6 billion increased 7% year-over-year and 8% on an Organic* basis with growth across all segments and regions. • Total company book-to-bill was 1.03 times, as orders dollars outpaced”
GE HealthCare Technologies Inc. reported fourth quarter ended December 31, 2023 results: revenue $5.2 billion, net income $403 million, EPS $0.88.
“growth. We’re confident heading into 2024 amid the backdrop of an improved capital equipment landscape.” Fourth Quarter 2023 Total Company Financial Performance • Revenues of $5.2 billion increased 5% on both a reported and Organic* basis year-over-year, driven by price and volume. • Total company book-to-bill was strong at 1.05 times, defined as Total orders”
GE HealthCare Technologies Inc. reported fourth quarter and fiscal year ended December 31, 2023 results: revenue $5.2 billion, net income $403 million. Guidance initiated.
“growth. We’re confident heading into 2024 amid the backdrop of an improved capital equipment landscape.” Fourth Quarter 2023 Total Company Financial Performance • Revenues of $5.2 billion increased 5% on both a reported and Organic* basis year-over-year, driven by price and volume. • Total company book-to-bill was strong at 1.05 times, defined as Total orders”
Betty D. Larson resigned as Chief People Officer at GE HealthCare Technologies Inc..
“On January 31, 2024, Betty D. Larson, Chief People Officer, notified GE HealthCare Technologies Inc. (the “Company”) that she will be resigning from her role at the Company and that her last day at the Company will be March 21, 2024.”
GE HealthCare Technologies Inc. incurred revolving credit of $1.0 billion with Citibank, N.A., as administrative agent at alternate base rate or adjusted Term SOFR rate plus an applicable margin maturing December 11, 2024.
“On December 13, 2023, GE HealthCare Technologies Inc. (the “Company”) entered into a 364-Day Revolving Credit Agreement (the “364-Day Revolving Credit Agreement”) among the Company, Citibank, N.A., as administrative agent, and the lenders named therein (the “Lenders”), which provides for a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $1.0 billion.”
GE HealthCare Technologies Inc. terminated 364-Day Revolving Credit Agreement with Citibank, N.A., as administrative agent, and the lenders named therein valued at $1.0 billion (effective 2023-12-13).
“On December 13, 2023, in connection with its entry into the 364-Day Revolving Credit Agreement, the Company terminated the 364-Day Revolving Credit Agreement, dated as of November 4, 2022, among the Company, Citibank, N.A., as administrative agent, and the lenders named therein, which provided for a $1.0 billion 364-day senior unsecured revolving credit facility that was scheduled to mature on January 2, 2024.”
GE HealthCare Technologies Inc. entered into 364-Day Revolving Credit Agreement with Citibank, N.A., as administrative agent, and the lenders named therein valued at $1.0 billion (effective 2023-12-13).
“On December 13, 2023, GE HealthCare Technologies Inc. (the “Company”) entered into a 364-Day Revolving Credit Agreement (the “364-Day Revolving Credit Agreement”) among the Company, Citibank, N.A., as administrative agent, and the lenders named therein (the “Lenders”), which provides for a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $1.0 billion.”
GE HealthCare Technologies Inc. reported third quarter ended September 30, 2023 results: revenue $4.8 billion, net income $375 million, EPS $0.83. Guidance raised.
“management. We remain confident in our 2023 outlook as we continue to innovate for customers and patients.” Third Quarter 2023 Total Company Financial Performance • Revenues of $4.8 billion increased 5% reported and 6% on an Organic basis* year-over-year, driven by volume and price. • Total company book-to-bill, defined as Total orders divided by Total revenues, was”
GE HealthCare Technologies Inc. reported second quarter ended June 30, 2023 results: revenue $4.8 billion, net income $418 million, EPS $0.91. Guidance raised.
“raising our top- and bottom-line guidance for the full year as we execute our precision care strategy. ” Second Quarter 2023 Total Company Financial Performance • Revenues of $4.8 billion increased 7% reported and 9% on an Organic basis* year-over-year. Foreign exchange negatively impacted growth by 2%. • Total company orders increased 6% organically, driven by”
GE HealthCare Technologies Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent auditor at the 2023-05-23 meeting.
“Our stockholders ratified the appointment of Deloitte & Touche LLP as our independent auditor for the fiscal year ending December 31, 2023, based on the following voting results:”
GE HealthCare Technologies Inc. shareholders approved Advisory vote on frequency of future say-on-pay votes at the 2023-05-23 meeting.
“Our stockholders approved one year as the frequency of future advisory votes on our named executive officers ’ compensation in an advisory vote, based on the following voting results:”
GE HealthCare Technologies Inc. shareholders approved Advisory vote on named executive officers' compensation at the 2023-05-23 meeting.
“Our stockholders approved our named executive officers ’ compensation in an advisory vote, based on the following voting results:”
GE HealthCare Technologies Inc. shareholders approved Election of 10 directors to serve until 2024 annual meeting at the 2023-05-23 meeting.
“Our stockholders elected 10 directors to each serve a one-year term until our 2024 annual meeting of stockholders or until his or her successor has been elected and qualified, based on the following voting results:”
Helmut Zodl changed role as Chief Financial Officer at GE HealthCare Technologies Inc..
“Mr. Saccaro will replace Helmut Zodl, who will cease to be our Chief Financial Officer and will become our Global Vice President, Special Projects and TSA Separation, effective June 1, 2023.”
James K. (Jay) Saccaro was named as Vice President and Chief Financial Officer at GE HealthCare Technologies Inc..
“On May 4, 2023, GE HealthCare Technologies Inc. (“GE HealthCare” or “we”) named James K. (Jay) Saccaro our Vice President and Chief Financial Officer, effective June 1, 2023.”
GE HealthCare Technologies Inc. reported First Quarter 2023 results: revenue $4.7 billion, net income $372 million, EPS $0.41. Guidance reaffirmed.
“• Revenues of $4.7 billion increased 8% reported and 12% on an Organic basis* year-over-year. Foreign exchange negatively impacted growth by 4%. Total company book-to-bill, defined as Total orders divided by Total revenues, was 1.01 times for the quarter, given strong revenue growth across all segments, led by Pharmaceutical Diagnostics (PDx) recurring sales. • Net income attributable to GE HealthCare was $372 million versus $389 million for the prior year, and Adjusted EBIT* was $664 million versus $599 million. • Net income margin was 7.9% versus 9.0% for the prior year, down 110 basis points (bp s) primarily impacted by interest expense. Adjusted EBIT margin* was 14.1% versus 13.8%, up 30 bps driven by volume, partially offset by mix. Inflation and planned investments were mostly offset by price and productivity actions. Adjusted EBIT margin* for the first quarter of 2023 grew 150 bps versus our estimated 1Q’22 Standalone Adjusted EBIT margin*. • Earnings per share (EPS) f rom conti”
GE HealthCare Technologies Inc. reported Fourth quarter and full year ended December 31, 2022 results: revenue Revenues of $4.9 billion, net income Net income was $554 million, EPS Earnings per share (EPS) from continuing operations were $1.21. Guidance reaffirmed.
“access to care, and an aging population globally. We are well positioned to deliver on our 2023 commitments.” Fourth quarter 2022 total financial performance • Revenues of $4.9 billion increased 8% and 13% on an Organic basis* year-over-year, driven by growth in Imaging, Patient Care Solutions (PCS), and Ultrasound. Acquisitions favorably impacted total revenue”
GE HealthCare Technologies Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue approximately $4.9 billion. Guidance initiated.
“solve some of the most significant clinical challenges with our precision care strategy.” Preliminary Fourth Quarter 2022 Results Fourth quarter 2022 revenue was approximately $4.9 billion. Revenue growth for the quarter was approximately 7% year over year. Organic revenue growth* for the quarter was approximately 12% year over year. Unless stated otherwise, all”
GE HealthCare Technologies Inc. completed a disposition involving General Electric Company (closed 2023-01-03).
“On January 3, 2023 (the “Distribution Date”), General Electric Company (“GE”) completed the previously announced distribution of approximately 80.1% of the shares of the common stock of GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “we,” “us,” or “our”) by GE to holders of GE common stock on a pro rata basis (the “Spin-Off”).”
GE HealthCare Technologies Inc. incurred term loan of $2.0 billion.
“On the Distribution Date, we drew down the full $2.0 billion available under the Term Loan Agreement.”
GE HealthCare Technologies Inc. entered into Trademark License Agreement with GE (effective 2023-01-03).
“if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. On January 3, 2023 (the “Distribution Date”), General Electric Company (“GE”) completed the previously announced distribution of approximately 80.1% of the shares of the common stock of GE HealthCare Technologies Inc.”
GE HealthCare Technologies Inc. entered into Employee Matters Agreement with GE (effective 2023-01-03).
“if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. On January 3, 2023 (the “Distribution Date”), General Electric Company (“GE”) completed the previously announced distribution of approximately 80.1% of the shares of the common stock of GE HealthCare Technologies Inc.”
GE HealthCare Technologies Inc. entered into Tax Matters Agreement with GE (effective 2023-01-03).
“if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. On January 3, 2023 (the “Distribution Date”), General Electric Company (“GE”) completed the previously announced distribution of approximately 80.1% of the shares of the common stock of GE HealthCare Technologies Inc.”
GE HealthCare Technologies Inc. entered into Transition Services Agreement with GE (effective 2023-01-03).
“if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. On January 3, 2023 (the “Distribution Date”), General Electric Company (“GE”) completed the previously announced distribution of approximately 80.1% of the shares of the common stock of GE HealthCare Technologies Inc.”
GE HealthCare Technologies Inc. entered into Separation and Distribution Agreement with GE (effective 2023-01-03).
“if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 1.01 Entry into a Material Definitive Agreement. On January 3, 2023 (the “Distribution Date”), General Electric Company (“GE”) completed the previously announced distribution of approximately 80.1% of the shares of the common stock of GE HealthCare Technologies Inc.”
Roland Rott was appointed as CEO, U at GE HealthCare Technologies Inc..
“Roland Rott 51 CEO, U”
Kevin M. O’Neill was appointed as CEO, Pharmaceutical Diagnostics at GE HealthCare Technologies Inc..
“Kevin M. O’Neill 54 CEO, Pharmaceutical Diagnostics”
Jan Makela was appointed as CEO, Imaging at GE HealthCare Technologies Inc..
“Jan Makela 54 CEO, Imaging”
Betty D. Larson was appointed as Chief People Officer at GE HealthCare Technologies Inc..
“Betty D. Larson 46 Chief People Officer”
Frank R. Jimenez was appointed as General Counsel and Corporate Secretary at GE HealthCare Technologies Inc..
“Frank R. Jimenez 57 General Counsel and Corporate Secretary”
George A. Newcomb was appointed as Chief Accounting Officer at GE HealthCare Technologies Inc..
“George A. Newcomb 55 Chief Accounting Officer”
Helmut Zodl was appointed as Chief Financial Officer at GE HealthCare Technologies Inc..
“Helmut Zodl 50 Chief Financial Officer”
Peter J. Arduini was appointed as President, Chief Executive Officer, and Director at GE HealthCare Technologies Inc..
“Peter J. Arduini 58 President, Chief Executive Officer, and Director”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.